Three signals this week point to a sector at a turning point.

Australia’s life sciences industry is accelerating—with stronger local capability, growing global engagement, and a more coordinated national R&D strategy taking shape.

But there’s a critical question we need to address.

As we move toward a more economically driven innovation model, how do we ensure health and medical research remains grounded in patient outcomes—not just commercial return?

In this week’s Top 3, I cover:
• The Ambitious Australia R&D strategy—and what it means for our sector
• A major capability investment in clinical trials infrastructure here in Sydney
• Why international partnerships will define our next phase of growth

If we get the balance right, we have a real opportunity to strengthen both our sector and outcomes for patients.